• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有在硫酸酯酶蛋白中保守的活性位点半胱氨酸错义突变的MPS IVA小鼠模型(Galns(tm(C76S)slu))

Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins.

作者信息

Tomatsu Shunji, Vogler Carole, Montaño Adriana M, Gutierrez Monica, Oikawa Hirotaka, Dung Vu Chi, Orii Tadao, Noguchi Akihiko, Sly William S

机构信息

Department of Pediatrics, Saint Louis University, Pediatric Research Institute, 3662 Park Ave., St. Louis, MO 63110-2586, USA.

出版信息

Mol Genet Metab. 2007 Jul;91(3):251-8. doi: 10.1016/j.ymgme.2007.02.009. Epub 2007 May 10.

DOI:10.1016/j.ymgme.2007.02.009
PMID:17498992
Abstract

Mucopolysaccharidosis IVA (MPS IVA) is an autosomal recessive disorder caused by deficiency of N-acetylgalactosamine-6-sulfate sulfatase (GALNS), required for degradation of keratan sulfate and chondroitin-6-sulfate. In order to study the effects of a missense mutation in the active site cysteine in the GALNS gene that is conserved in all mammalian sulfatases, we produced a p.C76S (an active site replacement) knock-in mouse by replacing the Cys76 with Ser in the endogenous murine Galns by targeted mutagenesis. Homozygous Galns(tm(C76S)slu) mice had no detectable GALNS enzyme activity. At age of 2-4 months, lysosomal storage was present primarily within reticuloendothelial cells such as Kupffer cells and spleen sinusoidal lining cells. Vacuolar change was present in glomerular visceral epithelial cells and was not present in hepatocytes or renal tubular cells. In the brain, hippocampal and neocortical neurons and meningeal cells showed lysosomal storage. Radiographs revealed no change in the skeletal bones of mice up to 12 months old. Thus, the Galns(tm(C76S)slu) mice had visceral storage of GAGs in organs but lacked the skeletal features of human MPS IVA. In contrast to a previously reported transgenic model (Galns(tm(hC79S.mC76S)slu)), in which the inactive human GALNS transgene was overexpressed, no reduction in other sulfatases was observed. In addition, the Galns(tm(C76S)slu) mice displayed milder storage. We conclude that the milder phenotype is characteristic of isolated GALNS deficiency while the more severe phenotype reflected in the Galns(tm(hC79S.mC76S)slu) mice was due to deficiency of other sulfatases caused by oversaturation of the sulfate modifying enzyme by the inactive human gene product.

摘要

黏多糖贮积症IVA(MPS IVA)是一种常染色体隐性疾病,由N - 乙酰半乳糖胺 - 6 - 硫酸酯硫酸酯酶(GALNS)缺乏引起,该酶是降解硫酸角质素和硫酸软骨素 - 6 - 硫酸酯所必需的。为了研究GALNS基因中活性位点半胱氨酸的错义突变的影响,该突变在所有哺乳动物硫酸酯酶中都是保守的,我们通过靶向诱变将内源性小鼠Galns中的半胱氨酸76替换为丝氨酸,构建了一个p.C76S(活性位点替换)敲入小鼠。纯合子Galns(tm(C76S)slu)小鼠没有可检测到的GALNS酶活性。在2 - 4个月大时,溶酶体贮积主要存在于网状内皮细胞中,如库普弗细胞和脾血窦衬里细胞。空泡变化存在于肾小球脏层上皮细胞中,而在肝细胞或肾小管细胞中不存在。在大脑中,海马和新皮质神经元以及脑膜细胞显示出溶酶体贮积。X线照片显示,12个月大的小鼠骨骼没有变化。因此,Galns(tm(C76S)slu)小鼠在内脏器官中有GAGs的贮积,但缺乏人类MPS IVA的骨骼特征。与先前报道的转基因模型(Galns(tm(hC79S.mC76S)slu))不同,在该模型中无活性的人类GALNS转基因过度表达,未观察到其他硫酸酯酶的减少。此外,Galns(tm(C76S)slu)小鼠表现出较轻的贮积。我们得出结论,较轻的表型是孤立性GALNS缺乏的特征,而Galns(tm(hC79S.mC76S)slu)小鼠中反映出的更严重表型是由于无活性的人类基因产物使硫酸修饰酶过度饱和导致其他硫酸酯酶缺乏所致。

相似文献

1
Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins.具有在硫酸酯酶蛋白中保守的活性位点半胱氨酸错义突变的MPS IVA小鼠模型(Galns(tm(C76S)slu))
Mol Genet Metab. 2007 Jul;91(3):251-8. doi: 10.1016/j.ymgme.2007.02.009. Epub 2007 May 10.
2
Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase.对人N-乙酰半乳糖胺-6-硫酸酯酶具有耐受性的MPS IVA小鼠(Galnstm(hC79S.mC76S)slu)的发育
Hum Mol Genet. 2005 Nov 15;14(22):3321-35. doi: 10.1093/hmg/ddi364. Epub 2005 Oct 11.
3
Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease.通过对黏多糖贮积症Ⅳ型A(Morquio A)病缺陷基因进行靶向破坏产生的N-乙酰半乳糖胺-6-硫酸酯酶缺乏症(Galns-/-)小鼠模型。
Hum Mol Genet. 2003 Dec 15;12(24):3349-58. doi: 10.1093/hmg/ddg366. Epub 2003 Oct 28.
4
Mutation and polymorphism spectrum of the GALNS gene in mucopolysaccharidosis IVA (Morquio A).黏多糖贮积症IVA(莫尔基奥氏综合征A)中GALNS基因的突变和多态性谱
Hum Mutat. 2005 Dec;26(6):500-12. doi: 10.1002/humu.20257.
5
Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase.重组人N-乙酰半乳糖胺-6-硫酸酯硫酸酯酶的表征及药代动力学研究
Mol Genet Metab. 2007 May;91(1):69-78. doi: 10.1016/j.ymgme.2007.01.004. Epub 2007 Mar 2.
6
Adeno-associated virus gene transfer in Morquio A disease - effect of promoters and sulfatase-modifying factor 1.腺相关病毒基因转移在莫氏病 A 型中的作用 - 启动子和硫酸酯酶修饰因子 1 的影响。
FEBS J. 2010 Sep;277(17):3608-19. doi: 10.1111/j.1742-4658.2010.07769.x.
7
Enzyme replacement therapy in a murine model of Morquio A syndrome.在莫尔基奥A综合征小鼠模型中的酶替代疗法。
Hum Mol Genet. 2008 Mar 15;17(6):815-24. doi: 10.1093/hmg/ddm353. Epub 2007 Dec 3.
8
Molecular analysis of Turkish mucopolysaccharidosis IVA (Morquio A) patients: identification of novel mutations in the N-acetylgalactosamine-6-sulfate sulfatase (GALNS) gene.土耳其黏多糖贮积症IVA型(莫尔基奥氏综合征A型)患者的分子分析:N-乙酰半乳糖胺-6-硫酸酯硫酸酯酶(GALNS)基因新突变的鉴定
Hum Mutat. 2002 Dec;20(6):477-8. doi: 10.1002/humu.9088.
9
Mucopolysaccharidosis type IV: N-acetylgalactosamine-6-sulfatase mutations in Tunisian patients.IV型黏多糖贮积症:突尼斯患者中的N-乙酰半乳糖胺-6-硫酸酯酶突变
Mol Genet Metab. 2006 Mar;87(3):213-8. doi: 10.1016/j.ymgme.2005.11.001.
10
Molecular heterogeneity in mucopolysaccharidosis IVA in Australia and Northern Ireland: nine novel mutations including T312S, a common allele that confers a mild phenotype.澳大利亚和北爱尔兰黏多糖贮积症IVA的分子异质性:九个新突变,包括T312S,一种导致轻度表型的常见等位基因。
Hum Mutat. 1998;11(3):202-8. doi: 10.1002/(SICI)1098-1004(1998)11:3<202::AID-HUMU4>3.0.CO;2-J.

引用本文的文献

1
Rat models of musculoskeletal lysosomal storage disorders and their role in pre-clinical evaluation of gene therapy approaches.肌肉骨骼溶酶体贮积症的大鼠模型及其在基因治疗方法临床前评估中的作用。
Mamm Genome. 2025 Mar 18. doi: 10.1007/s00335-025-10121-3.
2
Novel human recombinant N-acetylgalactosamine-6-sulfate sulfatase produced in a glyco-engineered strain.在糖基工程菌株中产生的新型人重组N-乙酰半乳糖胺-6-硫酸酯硫酸酯酶。
Heliyon. 2024 Jun 8;10(12):e32555. doi: 10.1016/j.heliyon.2024.e32555. eCollection 2024 Jun 30.
3
Mucopolysaccharidosis IVA: Current Disease Models and Drawbacks.
黏多糖贮积症 IVA:现有疾病模型及缺陷。
Int J Mol Sci. 2023 Nov 9;24(22):16148. doi: 10.3390/ijms242216148.
4
Bone Growth Induction in Mucopolysaccharidosis IVA Mouse.MPSIVA 小鼠的骨生长诱导
Int J Mol Sci. 2023 Jun 8;24(12):9890. doi: 10.3390/ijms24129890.
5
IgG Fusion Proteins for Brain Delivery of Biologics via Blood-Brain Barrier Receptor-Mediated Transport.用于通过血脑屏障受体介导的转运将生物制剂递送至大脑的IgG融合蛋白。
Pharmaceutics. 2022 Jul 15;14(7):1476. doi: 10.3390/pharmaceutics14071476.
6
The Inflammation in the Cytopathology of Patients With Mucopolysaccharidoses- Immunomodulatory Drugs as an Approach to Therapy.黏多糖贮积症患者细胞病理学中的炎症——以免疫调节药物作为治疗方法
Front Pharmacol. 2022 May 13;13:863667. doi: 10.3389/fphar.2022.863667. eCollection 2022.
7
Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy.AAV 介导的基因治疗治疗 IVA 型黏多糖贮积症的骨骼和非骨骼改变。
Nat Commun. 2021 Sep 9;12(1):5343. doi: 10.1038/s41467-021-25697-y.
8
Morquio Syndrome Presenting with Dural Band Pathology: A Case Report.以硬脊膜束带病变为表现的黏多糖贮积症IV型:一例报告
J Lab Physicians. 2020 Dec;12(4):285-288. doi: 10.1055/s-0040-1722548. Epub 2020 Dec 30.
9
Current therapies for Morquio A syndrome and their clinical outcomes.目前治疗莫尔基奥A综合征的疗法及其临床疗效。
Expert Opin Orphan Drugs. 2016;4(9):941-951. doi: 10.1080/21678707.2016.1214572. Epub 2016 Jul 28.
10
Mucopolysaccharidosis IVA and glycosaminoglycans.IVA型黏多糖贮积症与糖胺聚糖
Mol Genet Metab. 2017 Jan-Feb;120(1-2):78-95. doi: 10.1016/j.ymgme.2016.11.007. Epub 2016 Nov 29.